Loading...
Antimicrobial use is common in patients with terminal cancer because of concern for infection due to severe immunocompromise; moreover, various complications frequently mimic infection. However, despite conferring no survival advantage, antibiotic use in these end-stage patients contributes to adverse drug reactions, Clostridioides difficile infection, and antimicrobial resistance. Kim et al. performed a retrospective cohort study of 1143 adult patients who died with metastatic cancer after ≥4 days of hospitalization at an academic hospital in Seoul, Korea. Patients were categorized by whether or not they received palliative care consultation, and antibiotic consumption within 3 days of death was assessed with propensity score–weighted mult…